NRSN NeuroSense Therapeutics Ltd
3,167
$1.27
$0.06
(4.51%)
| Watchers | 3,167 |
| 52-Wk Low | $0.40 |
| 52-Wk High | $2.33 |
| Market Cap | $23.05M |
| Volume | 57,376.00 |
| 52-Wk High | $2.33 |
| 52-Wk Low | $0.40 |
NeuroSense Announces First Quarter 2024 Business UpdatePR Newswire • 4 days ago
NeuroSense Announces First Quarter 2024 Business Update NeuroSense Announces First Quarter 2024 Business Update PR Newswire CAMBRIDGE, Mass., May 2, 2024 CAMBRIDGE, Mass., May 2, 2024 /PRNewswire...
Share to Feed
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease NeuroSense and Genetika+ Initiate Precision Medicine...
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting NeuroSense Presents Positive Data...
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024 NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April...
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private...
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics NeuroSense Collaborates with Lonza to Identify...
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update NeuroSense Announces Year End 2023 Financial Results and Provides Business Update PR Newswire CAMBRIDGE, Mass., April...
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial PR Newswire CAMBRIDGE, Mass...
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule PR Newswire CAMBRIDGE, Mass., Feb. 7, 2024 CAMBRIDGE, Mass., Feb. 7...
NeuroSense Therapeutics (NASDAQ:NRSN Get Free Report) and China Health Industries (OTCMKTS:CHHE Get Free Report) are both medical companies, but which is the better business? We will...